**3.2 Arterio-venous fistula bacteraemia**

90 Technical Problems in Patients on Hemodialysis

mortality rate of 146 per 1000 person-years and catheters had the highest mortality rate of 261 per 1000 person-years. Catheter use conferred 1.5- to 3-fold increased risks in both infectious and all-cause mortality. A similar trend in both increased infectious and allcause mortality with AVGs was also observed but not significant on analysis

Apart from catheter-related infectious mortality, proposed alternative mechanisms for the increased death rates in patients with catheters have included reduced dialysis doses delivered by central catheters and a higher prevalence of co-morbid conditions in patients who dialyse via catheters. However, the latter was not confirmed after controlling for vascular disease and congestive cardiac failure (Pastan et al., 2002). No patterns of catheter use associated with increasing age or existing co-morbidities were ascertained from the more recent DOPPS III analysis. The usage of dialysis catheters in younger (18-70 year old) non-diabetics increased 2-fold in the US and up to 3-fold in some European countries

**3. Incidence, pathogenesis and bacteriology of access-related infections** 

Although the incidence of catheter-related bacteraemia is variable, the mean reported incidence is 3 episodes per 1000 catheter days (Dryden et al., 1991; Moss et al., 1990; Saad, 1999; Mokryzcki et al., 2000; Mokrzycki et al., 2001). Data from the HEMO study (Eknoyan et al., 2008) indicates that patients with central venous catheters have an increased relative mortality risk of 3.4 when compared with patients with AVFs (relative mortality risk of 1.4). The burden of catheter-related infection is high, with reported rates of metastatic infectious complications (e.g. osteomyelitis, endocarditis, septic arthritis or epidural abscess) of between 10% and 40% (Marr et al., 1997; Maya et al., 2007; Neilsen et al., 1998). *S. aureus* is responsible for the majority of vascular access infections, accounting for 70-90% of cases (Del

Gram-positive species are the culprit organisms in 61-95% of cases of catheter-related bacteraemia. In the prospective study by Hoen et al (1998), the most common causative organism was *S. aureus*. Coagulase-negative staphylococcal bacteraemia was almost as common as that caused by *S. aureus*. *Escherichia coli* and other aerobic gram negative bacilli were the next most commonly isolated organisms. The presumed portal of entry for these organisms was via the vascular access. In this study, 6 deaths were directly attributable to bacteraemia. The most common causative organisms under these circumstances were *S. aureus* and *Pseudomona*s with equal occurrence, and other Enterobacteriaciae making up the

Catheter-related bacteraemia may arise via two paths: (a) direct spread of microorganisms from the skin along the outside of the catheter leading to contamination of the bloodstream; or, (b) colonisation of the inner lumen of the catheter leading to the formation of biofilm and direct migration of organisms into the bloodstream. A biofilm is a multi-layered cell cluster with a strong propensity to adhere to polymer surfaces and provides a protected niche environment for microorganisms with physical barrier protection against antibiotics. Within the biofilm, bacteria exhibit increased growth rates, a higher cell density and more active gene transcription. This further contributes to the heightened resistance of bacteria to antibiosis (Fux et al., 2003). Even in the absence of

(Polkinghorne et al., 2004).

Rio el at., 2009; Gould, 2007).

**3.1 Catheter-related bacteraemia** 

remainder of isolated agents (Hoen et al., 1998).

(France, Germany, Italy and Spain) (Ethier, et al., 2008).

In those with AVF infection*, S. aureus* and *Staphylococcus epidermis* are most commonly responsible. Infection accounts for approximately one fifth of accesses being lost (Bhat et al., 1980). Microorganisms gain entry to the bloodstream during cannulation. In addition, the presence of pseudoaneuryms, peri-access haematomas, non-functioning clotted fistulae and manipulation of AVFs during non-dialysis interventions increase the risk of infection (Barraclough et al., 2009).

Recent evidence suggests that cannulation technique may have an important effect on the rates of bacteraemia related to AVFs. Over the last 30 years, the buttonhole cannulation technique has become increasingly popular. This technique involves repetitive cannulation of a small number of puncture sites, with the aim of creating a tunnel track into which the needles can be easily inserted. There are a number of benefits associated with using buttonhole cannulation for haemodialysis, particularly in the home environment. These benefits include easier and quicker needle insertion, less painful cannulation with the elimination of anaesthetic, reduction in "bad sticks", and reduction in hematoma formation (Doss et al., 2008; Hartig and Smyth, 2009). The alternative cannulation method, referred to as the rope ladder technique, involves needle puncture along the length of the fistula and is more inclined to give rise to small dilatations over the length of the fistula. However, several studies have suggested that the buttonhole technique is associated with an increased risk of access-related infection compared with the rope ladder method. Birchenough et al. (2008) established a positive correlation between use of the buttonhole cannulation technique and an increased risk for infection in adult patients on haemodialysis. Nesrallah et al. (2010) observed a significantly increased risk of *S. aureus* bacteremia infection with potentially fatal metastatic complications in patients receiving home nocturnal haemodialysis with buttonhole cannulation. They recommended advising prospective patients of the infection risks, and, in the absence of more rigorous studies, giving consideration to topical Mupirocin prophylaxis. Other studies have similarly reported increased access-related infection rates in association with buttonhole cannulation (Ludlow, 2010; Silva et al., 2010; Van Loon et al., 2010).

A subsequent retrospective observational cohort study in our unit involving 63 alternate nightly nocturnal haemodialysis and 172 conventional haemodialysis patients reported a statistically significant and clinically important increase in septic dialysis access events when nocturnal haemodialysis and buttonhole cannulation were used simultaneously (incidence rate ratio 3.0, 95% CI 1.04-8.66, p=0.04) (Van Eps et al., 2010). It is theorised that chronic bacterial colonisation of the buttonhole site may be the precursor to systemic infection, and that fibrosis surrounding the site may not provide as efficient a barrier as seen in those employing the rope ladder technique. This study highlights that increased infection control steps may be crucial in the setting of nocturnal haemodialysis and buttonhole technique.

#### **4. Preventative measures against access-related infection**

#### **4.1 Aseptic technique**

The method of handling the dialysis catheter is crucial. Stringent aseptic techniques must be employed, with KDOQI 2006 recommending washing the access site with antibacterial scrub and water followed by cleansing of the skin with 2% chlorhexidine/alcohol or 70% alcohol.

Hemodialysis Access Infections, Epidemiology, Pathogenesis and Prevention 93

bacteraemias (7 vs 35%, p<0.01) and a longer time to first bacteraemia (log rank score 8.68, P<0.01) (Johnson et al., 2002). The beneficial effect of mupirocin was entirely attributable to a reduction in staphylococcal infection (log rank 10.69, P=0.001) and was still observed when only patients without prior nasal *S. aureus* carriage were included in the analysis (log rank score 6.33, P=0.01). Median catheter survival was also significantly longer in the mupirocin

Recently, McCann & Moore (2010) published the results of their Cochrane systematic review in which they evaluated the benefits and harms of prophylactic topical antimicrobial agents on infectious complications among haemodialysis patients with central venous catheters. In a total of 10 randomised controlled trials involving 787 patients, the risk of catheter-related bacteraemia was reduced by topical exit site application of mupirocin (RR 0.17, 95%CI 0.07 - 0.43), polysporin triple ointment consisting of bacitracin, gramicidin and polymixin B (RR 0.40, 95% CI 0.19 – 0.86), and povidone-iodine ointment (RR 0.10, 95% CI 0.01 – 0.72).

In another meta-analysis topical antimicrobial agents reduced the rates of bacteraemia (risk rate ratio 0.22, 95% CI 0.12 – 0.40), exit site infection (RR 0.17, 95% CI 0.08 – 0.38), requirement for catheter removal and hospitalisation for infection compared with no

In spite of the demonstrated benefits of topical antimicrobial agents on catheter-associated infection rates, a real concern surrounding these agents is the potential risk of antibiotic resistance. Whilst these fears have not yet been realised, a number of groups have suggested that antimicrobial prophylactic therapy should be limited in duration and scope to minimise the possibility of promoting antimicrobial resistance. For example, a recent position statement issued by the European Renal Best Practice (ERBP) working group recommended the application of antimicrobial ointments (either mupirocin or polysporin ointment) after catheter placement only until the exit site has healed completely (Tordoir et al., 2007). They specifically advised against the use of these agents after the site has healed because of the

There is evidence that "locking" a catheter with a small amount of antimicrobial agent that remains within the catheter lumen can prevent bacteraemic episodes. These antimicrobial locks are thought to possess extra biofilm-removing properties. This is in contrast to heparin, which may serve to antagonise the antibacterial properties of certain antibiotics (Droste et al., 2003, Regamey et al., 1972) and may in fact promote biofilm

Nine randomised controlled trials looked at the potential role of antimicrobial locks versus the standard heparin lock. The mean baseline risk of catheter-related infection was 3.0 episodes per 1000 catheter days, with the catheter insertion duration ranging from 37-365 days (mean 146 days). Seven out of 9 trials used an antibiotic, 1 used taurolidine and 1 used 30% citrate. The different antimicrobial preparations included amikacin, cefazolin, cefotaxime, ciprofloxacin, EDTA, gentamicin, minocycline and vancomycin. Collectively, they showed a more than three-fold reduction in the occurrence of catheter-related bacteraemia, in addition to reductions in mortality and morbidity (Allon et al., 2008; Jaffer et al., 2008; Labriola et al., 2008;). Seven out of 9 of the studies reached statistical significance. The use of antimicrobial locks also significantly reduced the rate of catheter loss due to all complications (3 trials; n=399; RR 0.61, 95% CI 0.45-0.83) (Rabrinathan et al., 2009).

Mortalityrelated to infection was not reduced by any of these three agents.

group (108 vs 31 days, log rank score 5.9, P<0.05).

fear of emerging resistance and *Candida* colonisation.

antibiotics (James et al., 2008).

**4.4 Antimicrobial locks** 

formation (Shanks et al., 2006).

A multicentre prospective randomised trial (n=849) compared chlorhexidine-alcohol with povidone-iodine in the setting of post-operative surgical wounds and found that the chlorhexidine-alcohol preparation was associated with a significantly lower rate of surgical site infection (9.5% vs 16.1%, p=0.004, RR 0.59, 95% CI 0.41 – 0.85). However, in dialysis populations, there are only a few RCTs detailing the value of different antiseptic ointments. A small RCT studying povidone-iodine in subclavian catheters demonstrated a statistically significant improvement in exit site infections (5% vs 18%, p<0.02), tip colonisations and incidence of septicaemia compared with using sterile gauze dressings alone in the control group (Levin et al., 1991). The beneficial effect of povidone-iodine ointment was most marked in those with *S. aureus* nasal carriage (3-fold higher risk of subclavian catheterrelated septicaemia, p<0.05). No significant increase in adverse effects was observed with povidone-iodine.

There is no particular dressing type that has shown benefit over another. A chlorhexidineimpregnated foam dressing has not been found to provide extra protection against infection in an open labelled study (Camins et al., 2010), despite previous evidence to the contrary in patients in an intensive care setting (Timsit et al., 2009).

Maximal sterile barrier precautions were further studied in a recent Korean study. Using multivariate analyses, they found that the use of maximally sterile barrier precautions (odds ratio 5.205 95% CI 0.015 – 1.130, p=0.23) and use of antimicrobial coated catheters (odds ratio 5.269 95% CI 0.073 – 0.814, p=0.022) were independent factors associated with a lower risk of acquiring a central venous catheter-related bacteraemic episode (Lee at al., 2008). In another single centre study, the institution of a catheter monitoring system and a formal maintenance program following catheter insertion was associated with a reduction in the occurrence of catheter-related bacteraemia by 33% (Yoo et al., 2001). A Cochrane systematic review of randomised controlled trials (McCann and Moore, 2010) reported that transparent polyurethane dressing did not reduce the risk of catheter-related exit site infection or bacteraemia compared to dry gauze.

#### **4.2 Catheter care protocols**

It is well accepted practice in the critical care sector to adopt a strictly protocolised approach to the care of central venous catheters (Beathard and Urbanes, 2008; Pronovost et al., 2010). Care bundles are commonly used in the intensive care unit. A "care bundle" is a set of evidence-based interventions that are administered to many intensive care patients, with the aim of risk reduction. There is no randomised trial evidence in the haemodialysis population, but prospective observational data has shown a marked reduction in bacteraemic episodes from 6.7 to 1.6 per 1000 catheter days over a twenty four month study period using an infection prophylaxis protocol based on NKF-K/DOQI guidelines (2001). The main focus of the protocol was strict cleansing of the catheter hub at the time of use in the dialysis facility to avoid any potential contamination. Other vital elements to catheter care include the technical placement of the catheter, exit site care and the handling of dialysis connections.

#### **4.3 Topical antimicrobial agents**

Use of topical antimicrobial agents has been associated with reduced rates of bacteraemic episodes and catheter loss of any cause (Rabindranath et al., 2009). Our group was one of the first to demonstrate that topical exit site application of mupirocin, an antibiotic active against Gram-positive organisms, resulted in significantly fewer catheter-related bacteraemias (7 vs 35%, p<0.01) and a longer time to first bacteraemia (log rank score 8.68, P<0.01) (Johnson et al., 2002). The beneficial effect of mupirocin was entirely attributable to a reduction in staphylococcal infection (log rank 10.69, P=0.001) and was still observed when only patients without prior nasal *S. aureus* carriage were included in the analysis (log rank score 6.33, P=0.01). Median catheter survival was also significantly longer in the mupirocin group (108 vs 31 days, log rank score 5.9, P<0.05).

Recently, McCann & Moore (2010) published the results of their Cochrane systematic review in which they evaluated the benefits and harms of prophylactic topical antimicrobial agents on infectious complications among haemodialysis patients with central venous catheters. In a total of 10 randomised controlled trials involving 787 patients, the risk of catheter-related bacteraemia was reduced by topical exit site application of mupirocin (RR 0.17, 95%CI 0.07 - 0.43), polysporin triple ointment consisting of bacitracin, gramicidin and polymixin B (RR 0.40, 95% CI 0.19 – 0.86), and povidone-iodine ointment (RR 0.10, 95% CI 0.01 – 0.72). Mortalityrelated to infection was not reduced by any of these three agents.

In another meta-analysis topical antimicrobial agents reduced the rates of bacteraemia (risk rate ratio 0.22, 95% CI 0.12 – 0.40), exit site infection (RR 0.17, 95% CI 0.08 – 0.38), requirement for catheter removal and hospitalisation for infection compared with no antibiotics (James et al., 2008).

In spite of the demonstrated benefits of topical antimicrobial agents on catheter-associated infection rates, a real concern surrounding these agents is the potential risk of antibiotic resistance. Whilst these fears have not yet been realised, a number of groups have suggested that antimicrobial prophylactic therapy should be limited in duration and scope to minimise the possibility of promoting antimicrobial resistance. For example, a recent position statement issued by the European Renal Best Practice (ERBP) working group recommended the application of antimicrobial ointments (either mupirocin or polysporin ointment) after catheter placement only until the exit site has healed completely (Tordoir et al., 2007). They specifically advised against the use of these agents after the site has healed because of the fear of emerging resistance and *Candida* colonisation.

#### **4.4 Antimicrobial locks**

92 Technical Problems in Patients on Hemodialysis

A multicentre prospective randomised trial (n=849) compared chlorhexidine-alcohol with povidone-iodine in the setting of post-operative surgical wounds and found that the chlorhexidine-alcohol preparation was associated with a significantly lower rate of surgical site infection (9.5% vs 16.1%, p=0.004, RR 0.59, 95% CI 0.41 – 0.85). However, in dialysis populations, there are only a few RCTs detailing the value of different antiseptic ointments. A small RCT studying povidone-iodine in subclavian catheters demonstrated a statistically significant improvement in exit site infections (5% vs 18%, p<0.02), tip colonisations and incidence of septicaemia compared with using sterile gauze dressings alone in the control group (Levin et al., 1991). The beneficial effect of povidone-iodine ointment was most marked in those with *S. aureus* nasal carriage (3-fold higher risk of subclavian catheterrelated septicaemia, p<0.05). No significant increase in adverse effects was observed with

There is no particular dressing type that has shown benefit over another. A chlorhexidineimpregnated foam dressing has not been found to provide extra protection against infection in an open labelled study (Camins et al., 2010), despite previous evidence to the contrary in

Maximal sterile barrier precautions were further studied in a recent Korean study. Using multivariate analyses, they found that the use of maximally sterile barrier precautions (odds ratio 5.205 95% CI 0.015 – 1.130, p=0.23) and use of antimicrobial coated catheters (odds ratio 5.269 95% CI 0.073 – 0.814, p=0.022) were independent factors associated with a lower risk of acquiring a central venous catheter-related bacteraemic episode (Lee at al., 2008). In another single centre study, the institution of a catheter monitoring system and a formal maintenance program following catheter insertion was associated with a reduction in the occurrence of catheter-related bacteraemia by 33% (Yoo et al., 2001). A Cochrane systematic review of randomised controlled trials (McCann and Moore, 2010) reported that transparent polyurethane dressing did not reduce the risk of catheter-related exit site infection or

It is well accepted practice in the critical care sector to adopt a strictly protocolised approach to the care of central venous catheters (Beathard and Urbanes, 2008; Pronovost et al., 2010). Care bundles are commonly used in the intensive care unit. A "care bundle" is a set of evidence-based interventions that are administered to many intensive care patients, with the aim of risk reduction. There is no randomised trial evidence in the haemodialysis population, but prospective observational data has shown a marked reduction in bacteraemic episodes from 6.7 to 1.6 per 1000 catheter days over a twenty four month study period using an infection prophylaxis protocol based on NKF-K/DOQI guidelines (2001). The main focus of the protocol was strict cleansing of the catheter hub at the time of use in the dialysis facility to avoid any potential contamination. Other vital elements to catheter care include the technical placement of the catheter, exit site care and the handling of

Use of topical antimicrobial agents has been associated with reduced rates of bacteraemic episodes and catheter loss of any cause (Rabindranath et al., 2009). Our group was one of the first to demonstrate that topical exit site application of mupirocin, an antibiotic active against Gram-positive organisms, resulted in significantly fewer catheter-related

patients in an intensive care setting (Timsit et al., 2009).

bacteraemia compared to dry gauze.

**4.2 Catheter care protocols** 

dialysis connections.

**4.3 Topical antimicrobial agents** 

povidone-iodine.

There is evidence that "locking" a catheter with a small amount of antimicrobial agent that remains within the catheter lumen can prevent bacteraemic episodes. These antimicrobial locks are thought to possess extra biofilm-removing properties. This is in contrast to heparin, which may serve to antagonise the antibacterial properties of certain antibiotics (Droste et al., 2003, Regamey et al., 1972) and may in fact promote biofilm formation (Shanks et al., 2006).

Nine randomised controlled trials looked at the potential role of antimicrobial locks versus the standard heparin lock. The mean baseline risk of catheter-related infection was 3.0 episodes per 1000 catheter days, with the catheter insertion duration ranging from 37-365 days (mean 146 days). Seven out of 9 trials used an antibiotic, 1 used taurolidine and 1 used 30% citrate. The different antimicrobial preparations included amikacin, cefazolin, cefotaxime, ciprofloxacin, EDTA, gentamicin, minocycline and vancomycin. Collectively, they showed a more than three-fold reduction in the occurrence of catheter-related bacteraemia, in addition to reductions in mortality and morbidity (Allon et al., 2008; Jaffer et al., 2008; Labriola et al., 2008;). Seven out of 9 of the studies reached statistical significance. The use of antimicrobial locks also significantly reduced the rate of catheter loss due to all complications (3 trials; n=399; RR 0.61, 95% CI 0.45-0.83) (Rabrinathan et al., 2009).

Hemodialysis Access Infections, Epidemiology, Pathogenesis and Prevention 95

Taurolidine locks possess antimicrobial activity by producing methyl taurinamde products that bind to bacterial and fungal cell walls and cause damage. The antimicrobial effect is broad spectrum and has been shown to reduce the progression to biofilm production

A randomised controlled trial from the United Kingdom randomised subjects to receive either Taurolidine-Citrate lock (1.35% taurolidine & 4% citrate) or unfractionated heparin 5000units/mL. The primary outcome was time to first bacteraemic episode and secondary outcomes were total number of bacteraemic episodes and gram positive and gram negative infections. There was found to be no statistically significant difference in time to first bacteraemic episode (n=110). However, there was a significant reduction in gram negative infections (p=0.02). The main drawback to using Taurolidine-citrate locks is a greater need for thrombolytic therapy. Solomon et al. (2010) surmised that tauroldine-citrate usage impacted only infection of intraluminal origin and that better formulations with an improved anticoagulant profile should be sought. These findings echo those trends seen

Ethanol is an effective disinfectant with a broad spectrum of activity against a host of microorganisms. Its benefits include low toxicity, lack of antibiotic resistance, ready availability and low cost. Ethanol-containing catheter locks were initially used in oncology patients to maintain long term catheters and in those receiving total parenteral nutrition in order to manage catheter occlusion (Ball et al., 2003; Metcalf et al., 2004; Pennington and Pithie, 1987). As little as 60 minutes exposure to a 30% ethanol- 14% trisodium citrate locking solution has been show to effectively eradicate the common gram-positive and gramnegative bacteria colonising catheters (Takla et al., 2007). Maharaj et al. (2008) demonstrated an equally impressive effect on *Candida albicans* isolates within the same time frame. These antimicrobial benefits of ethanol appear to be associated with a neutral effect on the integrity of catheter material. A recent small study tested found no negative effect of a 30% ethanol-4% sodium citrate locking solution on catheters (Vercaigne et al., 2010). Guenu et al. (2007) similarly found no deterioration in silicone catheter viability following exposure to

Our unit is currently conducting a randomised controlled trial of heparin versus ethanol lock for the prevention of catheter-associated infection (Broom et al., 2009). This is a single centre prospective open-label study comparing 3mL 70% ethanol catheter lock head to head with a standard heparin lock. Using time to first catheter-related bacteraemia as the primary outcome, the study will hopefully elucidate further the benefit of ethanol as a useful

The healing properties of honey have been recognised since antiquity. Ancient Greeks and Egyptians used honey to aid in the healing of burns and sores. During World Ward I German physicians used honey and cod liver oil together as a surgical dressing for battle wounds. The antimicrobial properties of honey are related to its very high sugar content, which kills bacteria through dessication, and enzymatic production of hydrogen peroxide (glucose + H2O + O2 → gluconic acids + H2O2). The enzyme glucose oxidase also confers

(Torres-Viena et al., 2000). There are no reports of antibiotic resistance.

previously (Allon, 2003, Betjes and Van Agteren 2004; Taylor et al., 2008).

**4.5.2 Taurolidine** 

**4.5.3 Ethanol** 

**4.5.4 Honey** 

high concentrations of ethanol.

preventative measure against catheter-related infections.

Unfortunately, most of these trials were of short duration, being limited to 12 months follow-up or less. Consequently, the long-term risk:benefit of antimicrobial locks is uncertain. Significant side effects of antimicrobial locks that have been documented in the above trials included hypocalcaemia (Power et al., 2009) digital parasthesiae (Power et al., 2009) and ototoxicity in 10% of those using gentamicin based catheter locks (Dogra et al., 2002). Moreover, there are significant concerns that long term use of antimicrobial locks may promote multiresistant organisms (MROs). An American unit using a gentamicin/heparin lock observed the appearance of gentamicin resistant bacteraemia after a period of 6 months (Landry et al., 2010). The most common complications following such bacteraemias were catheter removal and hospital admission. Thus, despite a 95% decrease in the rate of catheter-related bacteraemia, there was the emergence of gentamicin resistant gram negative infections with tunnelled catheters being the most common access in the group. After stopping the gentamicin antimicrobial lock, the resistance to gentamicin dropped after 18 months.

#### **4.5 Non-antimicrobial locks**

#### **4.5.1 Citrate**

The spectre of antibiotic resistance has led nephrologists to seek alternative catheter lock agents. Sodium citrate has been utilised as an alternative anticoagulant to intradialytic heparin. Anticoagulant activity is brought about by reducing the free plasma calcium concentration and thus retarding the coagulation cascade. A 30% citrate solution will have antimicrobial and antibacterial properties. Citrate does not promote bacterial resistance and therefore has been proposed as the ideal catheter lock solution (Bleyer, 2007).

Power et al. (2009) studied 232 haemodialysis patients randomised to either 46.7% sodium citrate or 5% heparin locks post-dialysis for a 6 month period. In both groups, the rate of catheter-related bacteraemia was 0.7 events per 1000 catheter days with no significant difference between groups. There was a statistically significant increase in catheter thrombosis in the citrate group (p<0.001). All patients had a tunnelled twin catheter single lumen Tesio catheter.

Weijiner et al. (2005) had previously shown an added benefit of Trisodium citrate 30% in a randomised controlled trial incorporating 291 randomised haemodialysis patients. In this group however, 98/291 (34%) and 193/291 (66%) possessed tunnelled cuffed catheters and non-tunnelled catheters respectively. Catheter-related infection rates were 1.1 per 1000 catheter days in the trisodium citrate 30% group versus 4.1 per 1000 in the heparin group (p<0.001). There was found to be no difference in the rate of thrombotic events. This study showed a risk reduction for catheter-related bacteraemia of 87% for tunnelled catheters (p<0.001) and 64% for non-tunnelled catheters (p=0.05). There were fewer deaths from bacteraemia in the trisodium citrate 30% group (0 vs 5, p=0.028). Exit site infections were also reduced.

A concern with use of citrate relates to its chelating properties that can lead to hypocalcaemia with subsequent risk of ventricular arrhythmias. The death of a patient in 2000 from cardiac arrest following installation of 46.7% sodium citrate into a haemodialysis catheter prompted a Food and Drug Association (FDA) warning about its use (Food and Drug Administration, 2009). Many haemodialysis centres therefore avoid high doses of citrate in catheter locks. There is ongoing interest in using lower concentrations of sodium citrate, either alone or in combination with taurolidine or ethanol.

#### **4.5.2 Taurolidine**

94 Technical Problems in Patients on Hemodialysis

Unfortunately, most of these trials were of short duration, being limited to 12 months follow-up or less. Consequently, the long-term risk:benefit of antimicrobial locks is uncertain. Significant side effects of antimicrobial locks that have been documented in the above trials included hypocalcaemia (Power et al., 2009) digital parasthesiae (Power et al., 2009) and ototoxicity in 10% of those using gentamicin based catheter locks (Dogra et al., 2002). Moreover, there are significant concerns that long term use of antimicrobial locks may promote multiresistant organisms (MROs). An American unit using a gentamicin/heparin lock observed the appearance of gentamicin resistant bacteraemia after a period of 6 months (Landry et al., 2010). The most common complications following such bacteraemias were catheter removal and hospital admission. Thus, despite a 95% decrease in the rate of catheter-related bacteraemia, there was the emergence of gentamicin resistant gram negative infections with tunnelled catheters being the most common access in the group. After stopping the gentamicin antimicrobial lock, the resistance to gentamicin dropped after 18

The spectre of antibiotic resistance has led nephrologists to seek alternative catheter lock agents. Sodium citrate has been utilised as an alternative anticoagulant to intradialytic heparin. Anticoagulant activity is brought about by reducing the free plasma calcium concentration and thus retarding the coagulation cascade. A 30% citrate solution will have antimicrobial and antibacterial properties. Citrate does not promote bacterial resistance and

Power et al. (2009) studied 232 haemodialysis patients randomised to either 46.7% sodium citrate or 5% heparin locks post-dialysis for a 6 month period. In both groups, the rate of catheter-related bacteraemia was 0.7 events per 1000 catheter days with no significant difference between groups. There was a statistically significant increase in catheter thrombosis in the citrate group (p<0.001). All patients had a tunnelled twin catheter single

Weijiner et al. (2005) had previously shown an added benefit of Trisodium citrate 30% in a randomised controlled trial incorporating 291 randomised haemodialysis patients. In this group however, 98/291 (34%) and 193/291 (66%) possessed tunnelled cuffed catheters and non-tunnelled catheters respectively. Catheter-related infection rates were 1.1 per 1000 catheter days in the trisodium citrate 30% group versus 4.1 per 1000 in the heparin group (p<0.001). There was found to be no difference in the rate of thrombotic events. This study showed a risk reduction for catheter-related bacteraemia of 87% for tunnelled catheters (p<0.001) and 64% for non-tunnelled catheters (p=0.05). There were fewer deaths from bacteraemia in the trisodium citrate 30% group (0 vs 5, p=0.028). Exit site infections

A concern with use of citrate relates to its chelating properties that can lead to hypocalcaemia with subsequent risk of ventricular arrhythmias. The death of a patient in 2000 from cardiac arrest following installation of 46.7% sodium citrate into a haemodialysis catheter prompted a Food and Drug Association (FDA) warning about its use (Food and Drug Administration, 2009). Many haemodialysis centres therefore avoid high doses of citrate in catheter locks. There is ongoing interest in using lower concentrations of sodium

citrate, either alone or in combination with taurolidine or ethanol.

therefore has been proposed as the ideal catheter lock solution (Bleyer, 2007).

months.

**4.5.1 Citrate** 

lumen Tesio catheter.

were also reduced.

**4.5 Non-antimicrobial locks** 

Taurolidine locks possess antimicrobial activity by producing methyl taurinamde products that bind to bacterial and fungal cell walls and cause damage. The antimicrobial effect is broad spectrum and has been shown to reduce the progression to biofilm production (Torres-Viena et al., 2000). There are no reports of antibiotic resistance.

A randomised controlled trial from the United Kingdom randomised subjects to receive either Taurolidine-Citrate lock (1.35% taurolidine & 4% citrate) or unfractionated heparin 5000units/mL. The primary outcome was time to first bacteraemic episode and secondary outcomes were total number of bacteraemic episodes and gram positive and gram negative infections. There was found to be no statistically significant difference in time to first bacteraemic episode (n=110). However, there was a significant reduction in gram negative infections (p=0.02). The main drawback to using Taurolidine-citrate locks is a greater need for thrombolytic therapy. Solomon et al. (2010) surmised that tauroldine-citrate usage impacted only infection of intraluminal origin and that better formulations with an improved anticoagulant profile should be sought. These findings echo those trends seen previously (Allon, 2003, Betjes and Van Agteren 2004; Taylor et al., 2008).

### **4.5.3 Ethanol**

Ethanol is an effective disinfectant with a broad spectrum of activity against a host of microorganisms. Its benefits include low toxicity, lack of antibiotic resistance, ready availability and low cost. Ethanol-containing catheter locks were initially used in oncology patients to maintain long term catheters and in those receiving total parenteral nutrition in order to manage catheter occlusion (Ball et al., 2003; Metcalf et al., 2004; Pennington and Pithie, 1987). As little as 60 minutes exposure to a 30% ethanol- 14% trisodium citrate locking solution has been show to effectively eradicate the common gram-positive and gramnegative bacteria colonising catheters (Takla et al., 2007). Maharaj et al. (2008) demonstrated an equally impressive effect on *Candida albicans* isolates within the same time frame. These antimicrobial benefits of ethanol appear to be associated with a neutral effect on the integrity of catheter material. A recent small study tested found no negative effect of a 30% ethanol-4% sodium citrate locking solution on catheters (Vercaigne et al., 2010). Guenu et al. (2007) similarly found no deterioration in silicone catheter viability following exposure to high concentrations of ethanol.

Our unit is currently conducting a randomised controlled trial of heparin versus ethanol lock for the prevention of catheter-associated infection (Broom et al., 2009). This is a single centre prospective open-label study comparing 3mL 70% ethanol catheter lock head to head with a standard heparin lock. Using time to first catheter-related bacteraemia as the primary outcome, the study will hopefully elucidate further the benefit of ethanol as a useful preventative measure against catheter-related infections.

#### **4.5.4 Honey**

The healing properties of honey have been recognised since antiquity. Ancient Greeks and Egyptians used honey to aid in the healing of burns and sores. During World Ward I German physicians used honey and cod liver oil together as a surgical dressing for battle wounds. The antimicrobial properties of honey are related to its very high sugar content, which kills bacteria through dessication, and enzymatic production of hydrogen peroxide (glucose + H2O + O2 → gluconic acids + H2O2). The enzyme glucose oxidase also confers

Hemodialysis Access Infections, Epidemiology, Pathogenesis and Prevention 97

al., 2007). Within a set of immunocompromised patients, the rates of bacteraemia were reduced by cuffed catheters (2% vs 5%), although this did not achieve statistical significance

There is no clear evidence pointing to any differences in bacteraemia rates attained through usage of different catheter brands. Some groups have published data of long term tunnelled catheter usage (Tesio catheters, MedComp, Harleysville, Pennsylvania) highlighting bacteraemia rates similar to those achieved in arteriovenous fistulae. This particular group utilised strict protocols surrounding catheter care (Power et al., 2011). The four most commonly commercially available tunnelled catheters are the HemoSplit, Tesio twin catheter, Split-Catheter III and Permcath. A UK study examining catheter survival found that the Split Catheter III and Permcath fared worse than the HemoSplit and Tesio twin

There is no randomised trial evidence of any specific site of insertion conferring an increased risk of infection (Ruesch et al., 2002). In a large study of intensive care patients there was no statistically significant difference in the incidence of infection or duration of catheter amongst the insertion sites (Deshpande et al., 2005). Multivariate analyses from a number of studies have collectively suggested a higher rate of infection with the femoral vein location, with the infection risk with the jugular approach being greater than the subclavian approach (Breschan et al., 2007; Ishizuka et al., 2009, Ishizuka et al., 2008; Nagashima et al., 2006). These studies did not take into account baseline confounding

Trerotola et al.(2010) found no improvement in infection rates in tunnelled small bore

Since the early 1990's, there have been different types of central venous catheter antibiotic coatings trialled primarily in the critical care setting. There are no RCTs of antibiotic impregnated catheters in the chronic haemodialysis population. Raad et al. (1997) compared minocycline and rifampicin coated catheters head to head with untreated uncoated catheters, and found a significantly reduced rate of catheter related bacteraemia (0% versus 5%, respectively). This was a double blinded study (n=281) where the antibiotic coated catheters had been pre-treated with tri-idodecyclmethylammoniumchloride surfactant. The minocycline and rifampicin components were both active against methicillin-sensitive and methicillin-resistant *S. aureus*, and also had reported activity against gram negative bacilli and *Candida* species. Within a multicentre study of intensive care units, Maki et al. (1997) found a higher degree of bacterial colonisation of the catheter material in the uncoated as

Following these results, the United States CDC recommended the use of antibiotic coated catheters for those with a high rate of infection after full adherence to other infection control measures, such as maximal sterile barrier precautions. There was also a recommendation that in an adult with an expected need for a central venous catheter for more than five days

catheter. Infection rates were not specifically studied (Fry et al., 2008).

central venous catheters with the insertion of a polyester cuff.

(Andrivet et al., 1994).

**4.7.2 Catheter placement** 

**4.7.3 Catheter devices** 

**4.7.4 Antibiotic-impregnated catheters** 

compared to the antibiotic impregnated catheters.

an antibiotic impregnated catheter be used in preference.

variables.

acidity to the substance. The pH range of honey is 3.2-4.5, which is low enough to be inhibitory to many bacterial pathogens. Moreover, research has shown that peripheral B lymphocytes and T lymphocytes proliferate in the presence of honey concentrations as low as 0.1%, and that phagocytes are activated by honey at these same low concentrations (Abbas, 1997). Our unit has succeeded in showing the advantageous effects of Medihoney in a randomised controlled trial comparing thrice weekly exit site application of standardised antibacterial honey versus 2% mupirocin ointment on infection rates in patients with cuffed tunnelled central venous catheters (Johnson et al., 2005). Topical Medihoney led to comparable rates of catheter-related infection compared to those achieved with mupirocin, but conferred additional benefits including low cost, an excellent safety profile and lack of antibiotic resistance, especially mupirocin resistance.

#### **4.6 Nasal eradication of** *S. aureus*

Historically, nasal carriage of *S. aureus* has been associated with greater bacteraemic episodes with *S. aureus* in haemodialysis patients (Yu et al., 1986). Patients on chronic haemodialysis have been reported to have over twice the rate of *S. aureus* nasal colonisation as healthy controls. More recent data are in agreement with this, and it is widely believed that nasal colonisation provides a natural reservoir that facilitates ongoing habitation and propagation of *S. aureus* in human populations. (Elie-Turenne et al., 2010; Mermel et al., 2010). Nasal application of mupirocin has been proven to eradicate nasal carriage of *S.aureus* in up to 98.5% of cases (Taal et al., 2006). This strategy has been associated with a reduction in *S. aureus* bacteraemia compared to historical controls (Boelart et al., 1993), although again, use has been associated with the development of mupirocin resistance (Cavdar et al., 2004; Lobbedez et al., 2004). Currently however, there are no recommendations by the leading Nephrology bodies to perform routine eradication of nasal *S.aureus* in a bid to reduce catheter-related bacteraemia.

#### **4.7 The role of catheter design, structure and placement**

The first 30 days following catheter placement are vital to the prevention of bloodstream infection. During this period, technique should not be compromised as the main risk of entry is infection through medical staff interaction and the patient's normal skin microflora. After this time, the catheter is more vulnerable to internal sources of infection, possibly via the catheter hub, leading to subsequent haematogenous spread and bloodstream infection. Alternatively, infection at a distant internal site may lead to colonisation of the indwelling catheter (Knuttinen et al., 2009).

#### **4.7.1 Tunnelled versus non-tunnelled catheters**

The incidence of bacteraemia is greatly reduced in subjects using cuffed tunnelled catheters as opposed to non cuffed catheters. The majority of modern cuffed tunnelled catheters are made of either polyurethane or silicone. The cuffed portion, which lies in the subcutaneous tissue near the insertion site, creates a fibrous seal and provides an effective barrier against infection by preventing migration of bacteria down the outer surface of the catheter. Although there are no prospective randomised trials investigating infection-related morbidity between catheter types in the dialysis population, observed bacteraemia rates range from 0.16–0.86 per 100 days with non-tunnelled non-cuffed dialysis catheter to 0.016– 0.27 per 100 days with tunnelled cuffed catheters. Evidence from the non-haemodialysis setting showed lower infection rates in tunnelled catheters (Andrivet et al., 1994; Timsit et al., 2007). Within a set of immunocompromised patients, the rates of bacteraemia were reduced by cuffed catheters (2% vs 5%), although this did not achieve statistical significance (Andrivet et al., 1994).

There is no clear evidence pointing to any differences in bacteraemia rates attained through usage of different catheter brands. Some groups have published data of long term tunnelled catheter usage (Tesio catheters, MedComp, Harleysville, Pennsylvania) highlighting bacteraemia rates similar to those achieved in arteriovenous fistulae. This particular group utilised strict protocols surrounding catheter care (Power et al., 2011). The four most commonly commercially available tunnelled catheters are the HemoSplit, Tesio twin catheter, Split-Catheter III and Permcath. A UK study examining catheter survival found that the Split Catheter III and Permcath fared worse than the HemoSplit and Tesio twin catheter. Infection rates were not specifically studied (Fry et al., 2008).

#### **4.7.2 Catheter placement**

96 Technical Problems in Patients on Hemodialysis

acidity to the substance. The pH range of honey is 3.2-4.5, which is low enough to be inhibitory to many bacterial pathogens. Moreover, research has shown that peripheral B lymphocytes and T lymphocytes proliferate in the presence of honey concentrations as low as 0.1%, and that phagocytes are activated by honey at these same low concentrations (Abbas, 1997). Our unit has succeeded in showing the advantageous effects of Medihoney in a randomised controlled trial comparing thrice weekly exit site application of standardised antibacterial honey versus 2% mupirocin ointment on infection rates in patients with cuffed tunnelled central venous catheters (Johnson et al., 2005). Topical Medihoney led to comparable rates of catheter-related infection compared to those achieved with mupirocin, but conferred additional benefits including low cost, an excellent safety profile and lack of

Historically, nasal carriage of *S. aureus* has been associated with greater bacteraemic episodes with *S. aureus* in haemodialysis patients (Yu et al., 1986). Patients on chronic haemodialysis have been reported to have over twice the rate of *S. aureus* nasal colonisation as healthy controls. More recent data are in agreement with this, and it is widely believed that nasal colonisation provides a natural reservoir that facilitates ongoing habitation and propagation of *S. aureus* in human populations. (Elie-Turenne et al., 2010; Mermel et al., 2010). Nasal application of mupirocin has been proven to eradicate nasal carriage of *S.aureus* in up to 98.5% of cases (Taal et al., 2006). This strategy has been associated with a reduction in *S. aureus* bacteraemia compared to historical controls (Boelart et al., 1993), although again, use has been associated with the development of mupirocin resistance (Cavdar et al., 2004; Lobbedez et al., 2004). Currently however, there are no recommendations by the leading Nephrology bodies to perform routine eradication of nasal *S.aureus* in a bid to reduce

The first 30 days following catheter placement are vital to the prevention of bloodstream infection. During this period, technique should not be compromised as the main risk of entry is infection through medical staff interaction and the patient's normal skin microflora. After this time, the catheter is more vulnerable to internal sources of infection, possibly via the catheter hub, leading to subsequent haematogenous spread and bloodstream infection. Alternatively, infection at a distant internal site may lead to colonisation of the indwelling

The incidence of bacteraemia is greatly reduced in subjects using cuffed tunnelled catheters as opposed to non cuffed catheters. The majority of modern cuffed tunnelled catheters are made of either polyurethane or silicone. The cuffed portion, which lies in the subcutaneous tissue near the insertion site, creates a fibrous seal and provides an effective barrier against infection by preventing migration of bacteria down the outer surface of the catheter. Although there are no prospective randomised trials investigating infection-related morbidity between catheter types in the dialysis population, observed bacteraemia rates range from 0.16–0.86 per 100 days with non-tunnelled non-cuffed dialysis catheter to 0.016– 0.27 per 100 days with tunnelled cuffed catheters. Evidence from the non-haemodialysis setting showed lower infection rates in tunnelled catheters (Andrivet et al., 1994; Timsit et

antibiotic resistance, especially mupirocin resistance.

**4.7 The role of catheter design, structure and placement** 

**4.7.1 Tunnelled versus non-tunnelled catheters** 

**4.6 Nasal eradication of** *S. aureus* 

catheter-related bacteraemia.

catheter (Knuttinen et al., 2009).

There is no randomised trial evidence of any specific site of insertion conferring an increased risk of infection (Ruesch et al., 2002). In a large study of intensive care patients there was no statistically significant difference in the incidence of infection or duration of catheter amongst the insertion sites (Deshpande et al., 2005). Multivariate analyses from a number of studies have collectively suggested a higher rate of infection with the femoral vein location, with the infection risk with the jugular approach being greater than the subclavian approach (Breschan et al., 2007; Ishizuka et al., 2009, Ishizuka et al., 2008; Nagashima et al., 2006). These studies did not take into account baseline confounding variables.

#### **4.7.3 Catheter devices**

Trerotola et al.(2010) found no improvement in infection rates in tunnelled small bore central venous catheters with the insertion of a polyester cuff.

#### **4.7.4 Antibiotic-impregnated catheters**

Since the early 1990's, there have been different types of central venous catheter antibiotic coatings trialled primarily in the critical care setting. There are no RCTs of antibiotic impregnated catheters in the chronic haemodialysis population. Raad et al. (1997) compared minocycline and rifampicin coated catheters head to head with untreated uncoated catheters, and found a significantly reduced rate of catheter related bacteraemia (0% versus 5%, respectively). This was a double blinded study (n=281) where the antibiotic coated catheters had been pre-treated with tri-idodecyclmethylammoniumchloride surfactant. The minocycline and rifampicin components were both active against methicillin-sensitive and methicillin-resistant *S. aureus*, and also had reported activity against gram negative bacilli and *Candida* species. Within a multicentre study of intensive care units, Maki et al. (1997) found a higher degree of bacterial colonisation of the catheter material in the uncoated as compared to the antibiotic impregnated catheters.

Following these results, the United States CDC recommended the use of antibiotic coated catheters for those with a high rate of infection after full adherence to other infection control measures, such as maximal sterile barrier precautions. There was also a recommendation that in an adult with an expected need for a central venous catheter for more than five days an antibiotic impregnated catheter be used in preference.

Hemodialysis Access Infections, Epidemiology, Pathogenesis and Prevention 99

Institution of such protocols has resulted in a drastic reduction in catheter-related

The use of antibiotic lock solutions and topical antimicrobial ointment (mupirocin, povidone-iodine and polysporin triple antibiotic) has been shown to be effective in reducing bacteraemia. The benefits of citrate locks have been demonstrated by two meta-analyses (Yahav et al., 2008; Labriola et al., 2008). However, there are tenable concerns regarding cardiac arrhythmias, which may be circumvented by using lower concentrations of citrate that may compromise their antimicrobial potency. Topical medical-grade honey has proved efficacious against exit site infection. Prophylactic antibiotic at the time of insertion is frequently administered, although this intervention has never been validated in randomised

Antibiotic coatings are in wide usage in the critical care arena using non-cuffed nontunnelled catheters, but their usage has not crossed over to the dialysis unit. Novel therapies, such as thrombolytic agents and aspirin, require larger randomised studies before

We now have an increasing number of possible interventions in our armentarium to help us offer the best care to our patients. However, much more evidence in the form of clinical trials is needed to further elucidate the efficacy of these preventative measures, and other

Allon M. *(*2003). Prophylaxis against dialysis catheter related bacteraemia with a novel antimicrobial lock solution. *Clinical Infectious Disease*; 36: 1539-1544. Allon M. *(*2008). Prophylaxis against dialysis catheter-related bacteraemia: a glimmer of

Andrivet P, Bacquer A, Ngoc CV & Ferme C. (1994). Lack of clinical benefit from

http://www.anzdata.org.au/anzdata/AnzdataReport/33rdReport/ANZDATA33

Ball PA, Brokenshire E, Parry B, Merrie A, Gillanders L, McIlroy K & Plank L. (2003).

Barraclough KA, Hawley CM, Playford EG & Johnson DW. (2009). Prevention of access related infections. *Expert Reviews in Anti-Infective Therapy*; 7(10): 1185-200. Beathard GA & Urbanes A. (2008). Infection associated with tunnelled haemodialysis

Betjes MGH & Van Agteren M. *(*2004). Prevention of dialysis catheter-related sepsis with a

Bhat DJ, Tellis VA, Kohlberg WI, Driscoll B & Veith FJ. (1980). Management of sepsis

subcutaneous tunnel insertion of central venous catheters in immunocompromised

Ethanol locking as a possible treatment for microbial contamination of long-term

citrate-taurolidine-containing lock solution. *Nephrology Dialysis Transplantation;* 19:

involving expanded polytetrafluoroethylene grafts for haemodialysis access.

hope. *American Journal of Kidney Disease*; 51: 165–168.

patients. *Clinical Infectious Diseases*; 18(2): 199-206. ANZDATA Registry 2010 Report. (2010). The thirty third report.

central venous catheters. *Nutrition*; 19 (6): 570

catheters. *Seminars in Dialysis*; 21: 521-538.

bacteraemia reported in some American intensive care units (Pronovost et al., 2006).

controlled trials (Ryan et al., 2004).

their widespread use is advocated.

rdReport.pdf

1546-1551.

*Surgery;* 87(4): 445-50.

Abbas T. *(*1997) Royal treat. *Living in the Gulf*; 50-1.

potential treatments.

**6. References** 

More recently, a large retrospective study of central venous catheters in the critical care setting showed that there was a significant reduced incidence of catheter-related infection that was independent and complementary to the infection control precautions utilised. The incidence improved from 8.3 episodes of infection per 1000 patient days to 1.2 episodes per 100 patient days (Ramos et al., 2010). The body of evidence refers to only non-cuffed nontunnelled catheters, and has not led to the wide availability of such devices in the chronic haemodialysis population.

#### **4.8 Thrombolytic therapy**

Catheter-related bacteraemia may arise via the formation of an intraluminal thrombosis, which may then act as a nidus for the development of bacterial biofilm (McGee et al., 2003; Jain et al., 2009). Recombinant tissue plasminogen activator has been shown to be useful in catheter thrombus (Clase et al., 2001; Macrae et al., 2005; Tumlin et al., 2010) and some paediatric studies have looked into its potential effect on bacteraemia rates in the haemodialysis population. It has been shown that the prophylactic use of a catheter lock containing tissue plasminogen activator plus antibiotic can reduce the incidence of catheter– related bacteraemia, and may improve the infection-free survival times of central catheters at high risk of infection (Onder et al., 2009).

#### **4.9 Aspirin**

In vitro and in vivo animal studies of infective endocarditis have demonstrated aspirin to have direct anti-staphylococcus effects. It is theorised that the salicylic component of aspirin, which is the major biometabolite, inhibits the expression of two key *S. aureus* virulence genes involved in endovascular pathogenesis. A retrospective observational study over 10 years in a single haemodialysis centre found a lower rate of catheter-associated *S. aureus* bacteraemia in patients using aspirin at a daily dose of 325mg (Sedlacek et al., 2007).

### **5. Conclusions**

The goal of treatment of patients with end-stage kidney failure is to provide optimal dialysis while at the same time averting excess morbidity and mortality. It should always be borne in mind that this patient group is a vulnerable and relatively immunosuppressed cohort, often with appreciably significant co-morbidity. Evidence points towards the best outcome being achieved when dialysis is initiated using a native arteriovenous fistula, with the next best outcome with an arteriovenous graft. However, concomitant disease burden can make native access formation challenging.

The use of central venous catheters for dialysis purposes should be minimised and actively discouraged (ERBP Guidelines 2007, KDOQI 2006, CARI 2000) as they are associated with increased patient mortality, morbidity and cost of healthcare. The consequences of catheterrelated bacteraemia may be life-threatening, and could reach a 10% mortality rate (Saxena et al., 2002) and also effect cardiovascular morbidity. For those individuals where haemodialysis catheters are hard to avoid, a proactive approach is appropriate, and various preventative measures should be considered. The use of a catheter care protocol may be beneficial. The concept of the "care bundle" may be an extremely useful tool in the haemodialysis environment. In many ways the dialysis patient often has multi-organ involvement and a stepwise, astringent, highly protocolised pathway is appropriate. Institution of such protocols has resulted in a drastic reduction in catheter-related bacteraemia reported in some American intensive care units (Pronovost et al., 2006).

The use of antibiotic lock solutions and topical antimicrobial ointment (mupirocin, povidone-iodine and polysporin triple antibiotic) has been shown to be effective in reducing bacteraemia. The benefits of citrate locks have been demonstrated by two meta-analyses (Yahav et al., 2008; Labriola et al., 2008). However, there are tenable concerns regarding cardiac arrhythmias, which may be circumvented by using lower concentrations of citrate that may compromise their antimicrobial potency. Topical medical-grade honey has proved efficacious against exit site infection. Prophylactic antibiotic at the time of insertion is frequently administered, although this intervention has never been validated in randomised controlled trials (Ryan et al., 2004).

Antibiotic coatings are in wide usage in the critical care arena using non-cuffed nontunnelled catheters, but their usage has not crossed over to the dialysis unit. Novel therapies, such as thrombolytic agents and aspirin, require larger randomised studies before their widespread use is advocated.

We now have an increasing number of possible interventions in our armentarium to help us offer the best care to our patients. However, much more evidence in the form of clinical trials is needed to further elucidate the efficacy of these preventative measures, and other potential treatments.

#### **6. References**

98 Technical Problems in Patients on Hemodialysis

More recently, a large retrospective study of central venous catheters in the critical care setting showed that there was a significant reduced incidence of catheter-related infection that was independent and complementary to the infection control precautions utilised. The incidence improved from 8.3 episodes of infection per 1000 patient days to 1.2 episodes per 100 patient days (Ramos et al., 2010). The body of evidence refers to only non-cuffed nontunnelled catheters, and has not led to the wide availability of such devices in the chronic

Catheter-related bacteraemia may arise via the formation of an intraluminal thrombosis, which may then act as a nidus for the development of bacterial biofilm (McGee et al., 2003; Jain et al., 2009). Recombinant tissue plasminogen activator has been shown to be useful in catheter thrombus (Clase et al., 2001; Macrae et al., 2005; Tumlin et al., 2010) and some paediatric studies have looked into its potential effect on bacteraemia rates in the haemodialysis population. It has been shown that the prophylactic use of a catheter lock containing tissue plasminogen activator plus antibiotic can reduce the incidence of catheter– related bacteraemia, and may improve the infection-free survival times of central catheters

In vitro and in vivo animal studies of infective endocarditis have demonstrated aspirin to have direct anti-staphylococcus effects. It is theorised that the salicylic component of aspirin, which is the major biometabolite, inhibits the expression of two key *S. aureus* virulence genes involved in endovascular pathogenesis. A retrospective observational study over 10 years in a single haemodialysis centre found a lower rate of catheter-associated *S. aureus*

The goal of treatment of patients with end-stage kidney failure is to provide optimal dialysis while at the same time averting excess morbidity and mortality. It should always be borne in mind that this patient group is a vulnerable and relatively immunosuppressed cohort, often with appreciably significant co-morbidity. Evidence points towards the best outcome being achieved when dialysis is initiated using a native arteriovenous fistula, with the next best outcome with an arteriovenous graft. However, concomitant disease burden can make

The use of central venous catheters for dialysis purposes should be minimised and actively discouraged (ERBP Guidelines 2007, KDOQI 2006, CARI 2000) as they are associated with increased patient mortality, morbidity and cost of healthcare. The consequences of catheterrelated bacteraemia may be life-threatening, and could reach a 10% mortality rate (Saxena et al., 2002) and also effect cardiovascular morbidity. For those individuals where haemodialysis catheters are hard to avoid, a proactive approach is appropriate, and various preventative measures should be considered. The use of a catheter care protocol may be beneficial. The concept of the "care bundle" may be an extremely useful tool in the haemodialysis environment. In many ways the dialysis patient often has multi-organ involvement and a stepwise, astringent, highly protocolised pathway is appropriate.

bacteraemia in patients using aspirin at a daily dose of 325mg (Sedlacek et al., 2007).

haemodialysis population.

**4.8 Thrombolytic therapy** 

**4.9 Aspirin** 

**5. Conclusions** 

native access formation challenging.

at high risk of infection (Onder et al., 2009).

Abbas T. *(*1997) Royal treat. *Living in the Gulf*; 50-1.


Hemodialysis Access Infections, Epidemiology, Pathogenesis and Prevention 101

Doss S, Schiller B, Moran J. (2008). Buttonhole cannulation – an unexpected outcome.

Droste JC, Jeraj HA, MacDonald A & Farrington K. (2003). Stability and in vitro efficacy of

Eknoyan G, Beck GH, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J,

Elie-Turenne MC, Fernandes H, Mediavilla JR, Rosenthal M, Mathema B, Singh A, Cohen

Ethier J, Mendelssohn DC, Elder SJ, Hasegawa T, Akizawa T, Akiba T, Canaud BJ & Pisoni

Fistula First Breakthrough Initiative (FFBI). (2007). Summary of the FFBI buttonhole

Fry AC, Stratton J, Farrington K & Mahna K. (2008). Factors affecting long-term survival of

Fux CA, Stoodley P, Hall-Stoodley L & Costerton JW. *(*2003). Bacterial biofilms: a diagnostic and therapeutic challenge. *Expert Reviews in Anti-Infective Therapy*; 1: 667–683. Gould IM. (2007). MRSA bacteraemia. *International Journal of Antimicrobial Agents;* 30(Suppl

Guenu S, Heng AE, Charbonne F, Galmier MJ, Charles F, Deteix, Souweine B & Lartigue C.

Hartig V & Smyth W. (2009). Everyone should buttonhole: a novel technique for a regional

Hoen B, Paul-Dauphin A, Hestin D & Kessler M. (1998). *EPIBACDIAL: a multicenter* 

Ishani R, Collins AJ, Herzog C & Foley R. (2005). Septicaemia, access and cardiovascular

Ishizuka M, Nagata H, Takagi K & Kubota K. (2009). Femoral venous catheterization is a

solution. *Rapid Commununications in Mass Spectrometry*; 21:229-236.

Australian renal service. *Journal of Renal Care;* 35(3): 114-9.

of the American Society of Nephrology; 9: 869-876.

*of Investigative Surgery;* 22: 16–21.

catheter-related sepsis. *Journal of Antimicrobial Chemotherapy*; 51: 849–855. Dryden MS, Samson A, Ludlam HA, Wing AJ & Phillips I. (1991). Infective complications

in haemodialysis. *Journal of Hospital Infection*; 19: 257–262.

haemodialysis. *New England Journal of Medicine*; 347: 2010–2019.

technique environmental scan. http://www.fistulafirst.org.

*Nephrology Dialysis Transplantation;* 23(1): 275-281.

antibiotic-heparin lock solutions potentially useful for treatment of central venous

associated with the use of Quinton Permcath for long-term central vascular access

Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP & Toto R; Hemodialysis (HEMO) Study Group. (2002). Effect of dialysis dose and membrane flux in maintenance

TR, Pawar KA, Shahidi H, Kreiswirth BN, & Deitch EA. (2010). Prevalence and characteristics of *Staphylococcus aureus* colonization among healthcare professionals in an urban teaching hospital. *Infection Control and Hospital Epidemiology;* 31: 574–

RL. (2008). Vascular access use and outcomes: an international perspective from the dialysis outcomes and practice patterns study. *Nephrology Dialysis Transplantation*;

tunnelled haemodialysis catheters—a prospective audit of 812 tunnelled catheters.

(2007). Mass spectrometry and scanning electron microscopy study of silicone tunnelled dialysis catheter integrity after an exposure of 15 days to 60% ethanol

*prospective study of risk factors for bactaeremia in chronic haemodialysis patients.* Journal

disease in dialysis patients: The USRDS Wave 2 Study. *Kidney International;* 68:

major risk factor for central venous catheter-related bloodstream infection. *Journal* 

*Nephrology Nursing Journal*; 35(4): 417-419.

580.

23: 3219–3226.

1): S66–S70.

311–318.


Birchenough E, Moore C, Stevens K, & Stewart S. (2010). Buttonhole cannulation in adult

Bleyer AJ. (2007). Use of antimicrobial catheter lock solutions to prevent catheter-related bacteraemia. *Clinical Journal of the American Society of Nephrology*; 2(5): 1073-1078. Boddana P, Caskey F, Casula A & Ansell D. (2009). UK Renal Registry 11th Annual Report

Boelaert JR, Van Landuyt HW, Godard CA Daneels RF, Schurgers ML, Matthys EG, De

haemodialysis patients. *Nephrology Dialysis Transplantation*; 8(3): 235-239. Breschan C, Platzer M, Jost R, Schaumberger F, Stettner H & Likar R. (2007). Comparison of

Broom JK, O'Shea S, Govindarajulu S, Playford G, Hawley CM, Isbel NM, Campbell SB,

Associated infecTion in Haemodialysis patients. *BMC Nephrology*; 10: 23 Camins BC, Richmond AM, Dyer KL & Zimmerman HN. (2010). A crossover intervention

CARI *(Caring for Australasians with Renal Impairment) Guidelines. (2000). Dialysis Guidelines:* 

Cavdar C, Atay T, Zeybel M, Celik A, Ozder A, Yildiz S, Gulay Z & Camsari T. (2004).

Clase CM, Crowther MA, Ingram AJ & Cina CS. (2001). Thrombolysis for restoration of

Del Rio A, Cervera C, Moreno A, Moreillon P & Miro JM. (2009). Patients at risk of

Deshpande KS, Hatem C, Ulrich HL & Currie BP. (2005). The incidence of infectious

Dogra GK, Herson H, Hutchison B, Irish AB, Heath CH, Golledge C, Luxton G & Moody H.

study. *Journal of the American Society of Nephrology*; 13(8): 2133-9.

*Infection Control and Hospital Epidemio*logy; 31(11): 1118-23.

*Vascular Access.* Available at www.cari.org.au

*Thrombosis and Thrombolysis*; 11: 127-36.

*Dialysis*; 20: 67-70.

*Disease*; 48(4): S246–S253.

1443–51.

*Journal;* 37(5): 491-555.

53.

*Nephron Clinical Practice;,* 111 Suppl 1: c269-76.

patients on haemodialysis: an increased risk of infection? *Nephrology Nursing* 

(December 2008): Chapter 14 UK Renal Registry and international comparisons.

Baere YA, Gheyle DW, Gordts BZ & Herwaldt LA. (1993). Nasal mupirocin ointment decreases the incidence of *Staphylococcus aureus* bacteraemias in

catheter-related infection and tip colonization between internal jugular and subclavian central venous catheters in surgical neonates. *Anesthesiology;* 107(6): 946–

Mudge DW, Carpenter S, Johnson BC, Underwood N & Johnson DW (2009). Rationale and design of the HEALTHY-CATH trial: A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter

trial evaluating the efficacy of a chlorhexidine-impregnated sponge in reducing catheter-related bloodstream infections among patients undergoing haemodialysis.

Emergence of resistance in staphylococci after long-term mupirocin application in patients on continuous ambulatory peritoneal dialysis. *Advances in Peritoneal* 

patency to haemodialysis central venous catheters: a systemic review. *Journal of* 

complications of *Staphylococcus aureus* bloodstream infection. *Clinical Infectious* 

complications of central venous catheters at the subclavian, internal jugular, and femoral sites in an intensive care unit population. *Critical Care Medicine*; 33: 13–20. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF & Port FK. (2001). Type of vascular

access and mortality in US haemodialysis patients. *Kidney International* 2001; 60(4):

(2002) . Prevention of tunnelled haemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled


Hemodialysis Access Infections, Epidemiology, Pathogenesis and Prevention 103

Maharaj AR, Zelenitsky SA & Vercaigne LM. (2008). Effect of an ethanol/trisodium citrate

Maki DG, Stolz SM, Wheeler S & Mermel LA. (1997). Prevention of central venous catheter-

Marr KA, Sexton D, Conlon PJ Corey GR, Schwab SJ & Kirkland K. (1997). Catheter-related

Maya ID, Carlton D, Estrada E & Allon M. (2007). Treatment of dialysis catheter-related

McCann M & Moore ZE. (2010). Interventions for preventing infectious complications in

Mcgee DC & Gould MK. (2003). Preventing complications of central venous catheterisation.

Mermel LA, Eells SJ, Acharya MK, Cartony JM, Dacus D, Fadem S, Gay EA, Gordon S,

Metcalf SCL, Chambers ST & Pithie AD. (2004). Use of ethanol locks to prevent recurrent

Moist LM, Trpeski L, Na Y & Lok CE. (2008). Increased haemodialysis catheter use in

Mokrzycki MH, Jean-Jerome K, Rush H, Zdunek MP & Rosenberg SO. (2001). A randomized

Mokrzycki MH, Schroppel B, von Gersdorff G, Rush H, Zdunek M & Feingold R. (2000).

Moss AH, Vasilakis C, Holley JL, Foulks CJ, Pillai K & McDowell DE. (1990). Use of a

National Kidney Foundation KDOQI. (2001). Clinical practice guidelines and clinical

Nesrallah GE, Cureden M, Wong JHS & Pierratos A. (2010). Staphylococcus aureus

haemodialysis patients. *American Journal of Kidney Disease*; 16: 211-215. Nagashima G, Kikuchi T, Tsuyuzaki H, Kawano R, Tanaka H, Nemoto H, Taguchi K &

cuffed haemodialysis catheters. *Kidney International*; 59: 1935–1542.

randomized, controlled trial. *Annals of Internal Medcine*; 127: 257-66.

haemodialysis. *Annals of Internal Medicine*; 127: 275–280.

report. *American Journal of Kidney Disease*; 50(2): 289-95.

*New England Journal of Medicine*; 348: 1123-1133.

central line sepsis. *Journal of Infection*; 49: 20–22.

*Journal of Infection and Chemotherapy;* 12: 363–5.

kdoqi/guidelineupHDPDVA/index.htm

*Haemodialysis International;* 12(3): 342-327.

*Review*; 20(1): CD00689.

*of Nephrology*; 11: 2122–2127.

597.

1732.

hemodialysis catheter locking solution on isolated of Candida albicans.

related bloodstream infection by use of an antiseptic impregnated catheter: a

bacteraemia and outcome of attempted catheter salvage in patients undergoing

Staphylococcus aureus bactaeremia with an antibiotic lock: a quality improvement

haemodialysis patients with central venous catheters. *Cochrane Database Systematic* 

Lonks JR, Perl TM, McDougal LK, McGowan JE, Maxey G, Morse D & Tenover FC. (2010). Quantitative analysis and molecular fingerprinting of methicillin-resistant *Staphylococcus aureus* nasal colonization in different patient populations: a prospective, multicenter study. *Infection Control and Hospital Epidemiology;* 31: 592–

Canada and associated mortality risk: data from the Canadian Organ Replacement Registry 2001–2004. *Clinical Journal of the American Society of Nephrology;* 3: 1726–

trial of minidose warfarin for the prevention of late malfunction in tunnelled,

Tunnelled cuffed catheter associated infections in haemodialysis patients seropositive for the human immunodeficiency virus. *Journal of the American Society* 

silicone dual-lumen catheter with a Dacron cuff as a long-term vascular access for

Ugajin K. (2006). To reduce catheter-related bloodstream infections: is the subclavian route better than the jugular route for central venous catheterization?

practice for vascular access, update 2006. http://www.kidney.org/professionals/

bacteraemia and buttonhole cannulation: long-term safety and efficacy of


Ishizuka M, Nagata H, Takagi K, Horie T, Furihata M, Nakagawa A & Kubota K. (2008).

Jaffer Y, Selby NM, Taal MW, Fluck RJ & McIntyre CW. *(*2008). A meta-analysis of

Jain G, Allon M, Saddekni S, Barker JF & Maya ID. (2009). Does heparin coating improve

James MT, Conley J, Tonelli M, Manns BJ, MacRae J & Hemmelgarn BR. (2008). Meta-

Johnson DW, MacGinley R, Kay TD, Hawley CM, Campbell SB, Isbel NM & Hollett P.

Johnson DW, Van Eps C, Mudge DW, Wiggins KJ, Armstrong K & Hawley CM. (2005).

KDOQI 2006: National Kidney Foundation. (2006). Clinical practice guidelines and clinical

Knuttinen M, Bobra S, Hardman J & Gaba R. (2009). A review of evolving dialysis catheter

Labriola L, Crott R & Jadoul M. *(*2008). Preventing haemodialysis catheter-related

technologies. *Seminars in Interventional Radiology*; 26 (2): 106-114.

randomized trials. *Nephrology Dialysis Transplantation*; 23: 1666–1672. Landry DL, Braden GL, Gobeille SL & Haessler SD. (2010). Emergence of gentamicin-

subclavian Argyle catheter. *European Surgical Research*; 40: 197–202.

infection. *American Journal of Kidney Disease*; 51: 233–241.

*American Society of Nephrology*; 4: 1787-90.

*Transplantation*; 17: 1802-1807.

guidelineupHDPDVA/index.htm

*Kidney International*; 40(5): 934–8.

*Technologists Journal;* 20(1): 29-37.

*International*; 9: 189-95.

*Dialysis Transplantation*; 19(12): 3140-3143.

596-605.

External jugular Groshong catheter is associated with fewer complications than a

haemodialysis catheter locking solutions in the prevention of catheter-related

patency or reduce infection of tunnelled dialysis catheters? *Clinical Journal of the* 

analysis: antibiotics for prophylaxis against haemodialysis catheter-related infections. Alberta Kidney Disease Network. *Annals of Internal Medicine*; 148(8):

(2002). A randomised controlled trial of topical exit-site mupirocin application in patients with tunnelled cuffed haemodialysis catheters. *Nephrology Dialysis* 

Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in haemodialysis patients. *Journal of the American Society of Nephrology*; 16: 1456–1462.

practice for vascular access. http://www.kidney.org/professionals/kdoqi/

bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective

resistant bacteraemia in haemodialysis patients receiving gentamicin lock catheter prophylaxis. *Clinical Journal of the American Society of Nephrology*; 5 (10) : 1799-1804. Lee D, Jung K & Choi Y. (2008). Use of maximal sterile barrier precautions and/or

antimicrobial-coated catheters to reduce the risk of central venous catheter–related bloodstream infection. *Infection Control and Hospital Epidemiology*; 29(10): 947-950. Levin A, Mason AJ, Jindal KK, Fong IW & Goldstein MB. (1991). Prevention of

haemodialysis subclavian vein catheter infections by topical povidone-iodine.

Brunton J & Oreopoulos DG. (2004). Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years. *Nephrology* 

increased expense – is it worth it? *Canadian Association of Nephrology Nurses and* 

alteplase dwells in dysfunctional haemodialysis catheters. *Haemodialysis* 

Lobbedez T, Gardam M, Dedier H, Burdzy D, Chu M, Izatt S, Bargman JM, Jassal SV, Vas S,

Ludlow V. (2010). Buttonhole cannulation in haemodialysis: improved outcomes and

Macrae JM, Loh G, Djurdjev, Shalansky S, Werb R, Levin A, Kiaii M. (2005). Short and long


Hemodialysis Access Infections, Epidemiology, Pathogenesis and Prevention 105

Regamey C, Schaberg D & Kirby WM. (1972). Inhibitory effect of heparin on gentamicin concentrations in blood. *Antimicrobial Agents and Chemotherapy*; 1: 329–332. Ruesch S, Walder B & Tramer MR. (2002). Complications of central venous catheters:

Ryan JM, Ryan BM & Smith TP. (2004). Antibiotic prophylaxis in interventional radiology.

Saad TF. (1999). Bacteraemia associated with tunnelled, cuffed haemodialysis catheters.

Saxena AK, Panhotra BR, Uzzaman W, & Venkateshappa CK. (2002). The role of the

Shanks RM, Sargent L, Martinez RM, Graber M & O'Toole G. (2006). Catheter lock solutions

Silva GD, Silva RA, Niccolino AM, Pavanetti LC, Alasmar VL, Guzzardi R, Zanolli MB,

a Brazilian haemodialysis center. *Journal of Brasilian Nefrology;* 32(3): 257-62. Solomon LR, Cheesbrough JS, Ebah L & Al-Sayed T. (2010) *.* A randomized double-blind

Taal MW, Fluck RJ & McIntyre CW. (2006). Preventing catheter related infections in

Takla TA, Zelenitsky SA & Vercaigne LM. (2007). Effect of ethanol/trisodium lock on

Taylor C, Cahill J, Gerrish M, & Little J. *(*2008). A new haemodialysis catheter-locking agent reduces infections in haemodialysis patients. *Journal of Renal Care;* 34(3): 116-120. The European Renal Association - European Dialysis and Transplant Association. European

Timsit JF, Schwebel C, Bouadma L & Geffroy A. (2009). Chlorhexidine-impregnated sponges

Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, Kooman J, Martin-Malo A,

Torres-Viera C, Thauvin-Eliopoulos C, Souli M, DeGirolami P, Farris MG, Wennersten CB,

high-risk patients on haemodialysis. *Journal of Vascular Access*; 3(2): 74-9 Sedlacek M, Gemery JM, Cheung AL, Bayer AS & Remillard BD. (2007). Aspirin treatment is

*Journal of Vascular and Interventional Radiology*; 15(6): 547-56.

*American Journal of Kidney Disease*; 34: 1114–1124.

 *Medicine*; 30: 454–60.

49: 401-408.

602.

*Transplantation*; 21: 2247–2255.

*Diseases;* 55 (6): 1060-1068.

*Vascular Access*; 8(4): 262-7.

*Association*; 25: 301(12): 1231-41.

22 [Suppl 2]: ii88–ii117.

*Dialysis Transplantation;* 17: (Suppl 7):1–111.

internal jugular versus subclavian access—a systematic review. *Critical Care* 

*Staphylococcus aureus* nasal carriage and type of vascular access in the outcome of

associated with a significantly decreased risk of *staphylococcus aureus* bactaeremia in haemodialysis patients with tunnelled catheters. *American Journal of Kidney Diseases;* 

influence staphylococcal biofilm formation on abiotic surfaces. *Nephrology Dialysis* 

Guilhen JC & Araujo ID. (2010). Initial experience with the buttonhole technique in

controlled trial of taurolidine-citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis. *American Journal of Kidney* 

haemodialysis patients. *Current Opinion in Nephrology and Hypertension*; 15(6): 599-

microorganisms causing haemodialysis related catheter infections. *Journal of* 

best practice guidelines for haemodialysis (Part 1) ERA-EDTA. (2002). *Nephrology* 

and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomized controlled trial*. Journal of the American Medical* 

Pedrini L, Pizzarelli F, Tattersall J, Vennegoor M, Wanner C, ter Wee P & Vanholder R. (2007). EBPG on Vascular Access. *Nephrology Dialysis Transplantation*;

Sofia RD & Eliopoulos GM. (2000). Activities of taurolidine in vitro and in

mupirocin prophylaxis. *Clinical Journal of the American Society of Nephrology*; 5(6): 1047-53.


Nielsen J, Kolmos HJ & Espersen F. (1998). *Staphylococcus aureus* bacteraemia among patients

Onder AM, Chandar J, Billings A, Simon N, Gonzalez J, Francoeur D, Abitbol C & Zilleruelo

Pastan S, Soucie JM & McClellan WM. (2002). Vascular access and increased risk of death

Pennington CR & Pithie AD. (1987). Ethanol lock in the management of catheter occlusion.

Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA,

Polkinghorne KR, McDonald SP, Atkins RC & Kerr PG. (2004). Vascular access and all cause

Power A, Duncan N, Singh SK, Brown W, Dalby E, Edwards C, Lynch K, Prout V, Cairns T,

Power A, Singh SK, Ashby D, Cairns T, Taube D & Duncan N. (2011). Long-term Tesio

Pronovost PJ, Goeschel CA, Colantuoni E, Watson S, Lubomski LH, Berenholtz SM,

Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, Wall M, Harris R, Jones J,

Rabindranath KS, Bansal T, Adams J, Das R, Shail R, MacLeod AM, Moore C & Besarab A.

activator-tobramycin locks. *Pediatric Nephrology*; 24(11): 2233-43.

among haemodialysis patients. *Kidney International*; 62(2): 620–6.

States: Results from the DOPPS. *Kidney International*; 61(1): 305–16.

catheters. *American Journal of Kidney Disease*; 53(6): 1034-1041.

*Journal of Parenteral Nutrition*; 11: 507–5083.

*Current Opinion in Critical Care;* 12(6): 604-8.

study. *British Medical Journal*; 4;340: 309-315

blind trial. *Annals of Internal Medicine*; 127: 267-74.

experience. *Critical Care Medicine*; 39 (2): 245 -251.

1047-53.

15(2): 477–86.

*Transplantation*; 13: 139–145.

mupirocin prophylaxis. *Clinical Journal of the American Society of Nephrology*; 5(6):

undergoing dialysis—focus on dialysis catheter-related cases. *Nephrology Dialysis* 

G. (2009). Prophylaxis of catheter-related bacteremia using tissue plasminogen

Goodkin DA & Held PJ. (2002). Vascular access use in Europe and the United

mortality: a propensity score analysis. *Journal of the American Society of Nephrology*;

Griffith M, McLean A, Palmer A & Taube D. (2009). Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single center randomised control trial of sodium citrate versus heparin line locks for cuffed central venous

catheter access for haemodialysis can deliver high dialysis adequacy with low complication rates. *Journal of Vascular and Interventional Radiology;* 22(5): 631-637 Pronovost PJ, Holzmueller CG, Clattenburg L, Berenholtz S, Martinez EA, Paz JR&

Needham DM. (2006). Team care: beyond open and closed intensive care units.

Thompson DA, Sinopoli DJ, Cosgrove S, Sexton JB, Marsteller JA, Hyzy RC, Welsh R, Posa P, Schumacher K & Needham D. (2010). Sustaining reductions in catheter related bloodstream infections in Michigan intensive care units: observational

Buzaid A, Robertson C, Shenaq S, Curling P, Burke T & Ericsson C. (1997). Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-

(2009). Systematic review of antimicrobials for the prevention of haemodialysis catheter-related infections. *Nephrology Dialysis Transplantation*; 24(12): 3763-74. Ramos ER, Reitzel R, Jiang Y, Hachem RY, Chaftari AM, Chemaly RF, Hackett B,

Pravinkumar SE, Nates J, Tarrand JJ & Raad II. (2010). Clinical effectiveness and risk of emerging resistance associated with prolonged use of antibioticimpregnated catheters: More than 0.5 million catheter days and 7 years of clinical


**7** 

**Acute and Chronic Catheter in Hemodialysis** 

Reliable and sustained access to the circulation is mandatory for the provision of long-term hemodialysis which is critical to the survival of patients with end-stage renal disease (ESRD). An ideal vascular access provides adequate blood flow to meet the hemodialysis prescription, with minimal complications due to infection or thrombosis. The natural arteriovenous fistula (AVFs) comes closest to meeting these criteria while arteriovenous grafts (AVGs) and central venous catheters (CVCs) present other vascular access options. In the United States, promoting a major shift in using fistula as first-choice vascular access has been strongly recommended by the 2001 Kidney Disease Outcome Quality Initiative (K/DOQI) vascular access guideline (NKF-DOQI 2001) and the "Fistula First" national initiative (Tonnessen et al 2005). Ideally, every patient would initiate dialysis with a mature fistula suitable for cannulation. In real clinical setting, this is not true due to combination of the following factors including (i) lacking nephrology follow-up at the time of ESRD, (ii) late nephrology referral, (iii) poor or no planning of fistula placement, (iv) inadequate fistula

maturation and (v) poor vascular preparation due to prior venous cannulation.

while 39% and 11% depends on a CVC or AVG, respectively (James et al 2009).

In current practice, 20-50% of attempted AVFs fail to mature adequately. Despite a recent increase in the number of prevalent patients dialyzing with an AVF (47%) in the US following the fistula-first initiative, 28% of prevalent patients remain dependent on an AVG and 25% on a CVC. In Canada, recent data demonstrate that 50% of patients use an AVF,

Sadly, hemodialysis CVCs are increasingly being introduced in patients requiring emergency or chronic renal replacement therapy. Table 1 outlines the advantages and disadvantages of CVCs. The percentages of patients undergoing dialysis with vascular catheters are increasing in Europe, ranging from 15% (Germany) to 50% (United Kingdom) of all hemodialysis patients. In the United States, up to 60% of patients start hemodialysis with CVCs (Pisoni et al 2002). Over the last decade, the number of patients using CVCs for hemodialysis doubled (Rayner et al 2004). According to the Dialysis Outcomes and Practice Patterns Study, 18% of patients with end-stage renal failure in the United States and 24% of those in Great Britain have been dialysed with such catheters (Quarello et al 2006). Table 2 summarizes the indication for using CVCs. Recent studies indicate that CVCs are used in 20- 25% of incident (<6 months) chronic kidney disease (CKD) stage 5 patients and still used in 10-20% of prevalent hemodialysis patients (> 6 months) (Rayner et al 2004a, Moist et all 2007). The use of CVCs has been complicated by higher rates of thrombosis, dysfunction,

**1. Introduction** 

Andrew S. H. Lai1 and Kar Neng Lai2

*Queen Mary Hospital, University of Hong Kong* 

*1Department of Diagnostic Radiology* 

*2Department of Medicine* 

*Hong Kong* 

experimental enterococcal endocarditis. *Antimicrobial Agents and Chemotherapy*; 44(6): 1720-1724.


http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm : 1–26.

